|
US2020376109A1
|
|
Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
|
|
US2020323946A1
|
|
Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
|
|
US2017253551A1
|
|
Systems and methods for producing synthetic hypericin
|
|
CN109071397A
|
|
System and method for producing synthesis hypericin
|
|
US2017007682A1
|
|
Multivalent stable vaccine composition and methods of making same
|
|
WO2016007797A1
|
|
Multivalent stable vaccine composition and methods of making same
|
|
WO2015061682A2
|
|
Novel peptides and analogs for use in the treatment of macrophage activation syndrome
|
|
EP3044229A1
|
|
Novel peptides and analogs for use in the treatment of oral mucositis
|
|
US2014328929A1
|
|
Method of Preventing Acute Graft-Versus-Host Disease using Oral Beclomethasone Dipropionate
|
|
AU2012255132A1
|
|
Thermostable vaccine compositions and methods of preparing same
|
|
EP2932973A1
|
|
Formulations for use in the treatment of skin conditions
|
|
CA2745930A1
|
|
Topically active steroids for use in radiation and chemotherapeutics injury
|
|
NZ587119A
|
|
Use of beclomethasone dipropionate in the treatment of an interstitial lung disease
|
|
MY148085A
|
|
Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
|
|
CN101060848A
|
|
Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
|
|
EP1392321A1
|
|
Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
|
